Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.

Emma Zattarin, Rita Leporati, Francesca Ligorio, Riccardo Lobefaro, Andrea Vingiani, Giancarlo Pruneri, Claudio Vernieri

Research output: Contribution to journalArticlepeer-review

Abstract

Hormone receptor-positive breast cancer (HR+ BC) accounts for approximately 75 BC in recent years, primary or acquired resistance to endocrine therapies still represents a clinically relevant issue, and is largely responsible for disease recurrence after curative surgery, as well as for disease progression in the metastatic setting. Among the mechanisms causing primary or acquired resistance to endocrine therapies is the loss of estrogen/progesterone receptor expression, which could make BC cells independent of estrogen stimulation and, consequently, resistant to estrogen deprivation or the pharmacological inhibition of estrogen receptors. This review aims at discussing the molecular mechanisms and the clinical implications of HR loss as a result of the therapies used in the neoadjuvant setting or for the treatment of advanced disease in HR+ BC patients.
Original languageEnglish
JournalCells
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 1 2020

Keywords

  • *breast cancer
  • *(neo)adjuvant therapy
  • *clonal selection
  • *conversion
  • *endocrine therapies
  • *hormone receptors
  • *intratumor heterogeneity
  • *re-characterization
  • *tumor recurrences

Fingerprint Dive into the research topics of 'Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.'. Together they form a unique fingerprint.

Cite this